Program

 
 

Day 1 - Wednesday, 28 October 

 
 14:00 CETOpening of the Meeting
Anne-Geneviève Marcelin
 
 14:05 CET

Ghosn Jade, 2018
Andrea De Luca Lecture: 
The Top 10 Important Observations of the Last Year Affecting Clinical Management
Jade Ghosn, MD, PhD - Bichat University Hospital, France

 
    
 Session 1:  Challenges in Central and Eastern Europe
Chair: Anne-Mieke Vandamme
 
 14:25 CET

Noori,Teymur 2018
Epidemiology of HIV and Hepatitis in CEE
Teymur Noori - European Centre for Disease Prevention and Control (ECDC), Sweden

 
 14:40 CET

Streinu Cercel, Anca 2017

Transmitted and Acquired Resistance: Special Populations
Anca Streinu - Cercel, MD, PhD - National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Romania 

 
 14:55 CET

Infection with subtype D adversely affects the live expectancy among people living with HIV – data from Northwestern Poland
Milosz Parczewski, MD, PhD - Pomeranian Medical University, Poland

 #1
 15:05 CETHIV TRACE VS PHYLOGENETIC ANALYSIS: UNRAVELING TRANSMISSION CLUSTERS IN SPAIN
Federico Garcia - Hospital Universitario San Cecilio, Spain
 #2
 15:15 CET

Prevalence and evolution of transmitted HIV drug resistance in Belgium between 2013 and 2019
Virginie Mortier - University Hospital Gent, Belgium

 #3
 15:25 CET Live Discussion 
 15:45 CETCoffee Break - 15 min & Meet the Speaker 
    
 Special Session:  First Day Treatment – the European Perspective
 
 16:00 CETFirst Day Treatment, Definition, and Review of Data 
 16:15 CETImplementing First Day Treatment in Europe: Western Perspective 
 16:30 CET

Milosz ParczewskiMD, PhD

Implementing First Day Treatment in Europe: Central and Eastern Perspective
Milosz Parczewski, MD, PhD - Pomeranian Medical University, Poland

 
 16:45 CET Live Discussion 
 17:00 CET Break  
    
 Session 2: Clinical Management of HIV
Chair: Gary Rubin
 
 17:10 CET

Patient-Reported Outcomes and Studies
Martin Duracinsky, MD, PhD - Paris Diderot University, France

 
 17:25 CET
Clinical Case
Romain Palich, MD - Pitié - Salpêtrière Hospital, France
 
 17:40 CET

Factors associated with the emergence of resistance mutations in patients failing dual or triple-integrase inhibitors-based regimen in a French national survey 
Anne-Geneviève Marcelin, MD, PhD - France

 #4
 17:50 CET

HIV DNA DRUG RESISTANCE GENOTYPING, BASED ON ILLUMINA SEQUENCING, AS DECISIONAL MARKER FOR cART OPIMISATION IN CLINICAL PRACTICE: ADDED VALUE, GAPS AND FUTURE DIRECTIONS
Ali Si-Mohammed, PharmD, PhD -CHU Dijon, France

 #5
 18:00 CET

High efficacy after switching to integrase strand transfer inhibitors (INSTI) in PLWH with undetectable viremia and past virological failure and/or resistance
Roberta Gagliardini, MD - Lazzaro Spallanzani National Institute For Infectious Diseases Irccs, Rome, Italy

 #6
 18:15 CETLive Discussion 
 18:30 CETMeet the Speaker Session 
    
  18:30 CEST Poster viewing session 1 (odd numbers) 
    
 

Day 2 - Thursday, 29 October 

 
 Session 3: Resistance to Long-Acting Antivirals
Chair: Maurizio Zazzi
 
 14:00 CET

Resistance to Long-Acting Antivirals
Anne-Geneviève Marcelin, PharmD, PhD - Sorbonne Université, France

 
 14:15 CET


Patients with Poor or Good Adherence: Who Will Benefit More from Long Acting Therapy?
Charles Flexner, MD - Johns Hopkins University School of Medicine, USA

 
  14:30 CETEmergence and Persistence of Integrase Mutation T97A Selected by Dolutegravir
Kristi Huik - HIV Dynamics and Replication Program, NCI, NIH, USA
 #7
 14:40 CETEvaluation of HIV-1 RNA and DNA mutational load in HIV-1 infected heavily treatment-experienced patients harbouring multi-drug resistant strains
Daniele Armenia, MD - Saint Camillus International University of Health Sciences, Italy
 #8
 14:50 CET

Long-term Bictegravir and Dolutegravir Resistance Selections Initiated with HIV-1 Containing M184V in Reverse Transcriptase
Kristen Andreatta -  Gilead Sciences, USA

 #9
    
 15:00 CETLive Discussion 
    
 15:20 CESTCoffee Break and Meet the Speaker 
    
 Industry-Sponsored Symposium 
 
 15:35 CET Symposium: click here to see the program 
    
 16:35 CET Break  
    
                   Poster Session
 
 16:45 CETBest of Posters 
  

Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates
Alessia Giannini - University Of Siena, Italy

 #13
  Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry
Francesco Saladini, PhD - University Of Siena, Italy
 #14
  Two-drug regimen (2DR) for initial HIV treatment? – Lessons learned from 20 years RESINA cohort
Nadine Lübke- University of Düsseldorf, Germany
#15
    
    
  17:15 CETGuided Poster Tours - 4 parallel sessions 
  Topic 1: Epidemiology / Viral Spread
Moderator: Dimitrios Paraskevis
 
  Dynamics of HIV-1 transmission clusters in North and Central Italy over the years 2012-2019
Claudia Alteri, PhD - University Of Milan, Italy
 #17
  Transmitted drug resistance to integrase based first-line HIV antiretroviral treatment in the MeditRes HIV collaboration
Federico García - Hospital Universitario San Cecilio, Spain
 #18
   Exploring Molecular Characteristics and Evolutionary Dynamics of the HIV-1 Epidemic in Montenegro Through Phylogenetic Analyses
Snezana Dragas, PhD - Clinical Centre , Clinic For Infectious Disease, Montenegro
 #19
  Prevalence and spatiotemporal dynamics of the HIV-1 circulating recombinant form 03_AB (CRF03_AB) in the former Soviet Union
Ekaterina Ozhmegova, MD - Gamaleya National Research Center Of Epidemiology And Microbiology, Russia
 #20
    
  Topic 2: Clinical management 
  Cabotegravir + Rilpivirine Every 2 Months Is Noninferior to Monthly: ATLAS-2M Study
Paul D. Benn - ViiV Healthcare, UK
 #21
  Short- and long-term direct medical costs of late and very late HIV presentation 
Lisbeth Versteegh - Erasmus MC, the Netherlands
 #22
  Treatment outcome among people living with HIV starting first-line rapid or GRT guided ART from 2015 to 2018
Andrea De Vito, MD - University Of Sassari, Italy
 #23
  Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients
Yagai Bouba, MSc - University of Rome "Tor Vergata", Italy
 #24
    
  Topic 3: Resistance 
  DTG+3TC vs DTG+TDF/FTC (GEMINI1&2): Confirmed Virologic Withdrawals Through Week 96
Jean van Wyk, MB,ChB - Viiv Healthcare, UK
 #25
  Emergence of Resistance in HIV-1 Integrase following Dolutegravir Treatment in Participants Aged 4 Weeks to <18 Years:  Results from the IMPAACT P1093 Study
Cindy Vavro - ViiV Healthcare, USA
 #26
  Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab
Henri Jullien - Syneos Health, France
 #27
  In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations
Federica Giammarino, MD - University Of Siena, Italy
 #28
    
   Topic 4: HIV-DNA
Moderator: Francesca Ceccherini
 
  DETECTION IN HIV PROVIRAL DNA OF DRUG RESISTANCE MUTATIONS IN PATIENTS WITH LOW PERMANENT VIRAL LOADS
Pablo Ferrer - Hospital Clinico Universidad De Chile, Chile
 #29
  HIV-DNA DECAY IN ART-NAÏVE PATIENTS STARTING A DTG-BASED DUAL VS TRIPLE THERAPY 
Francesca Lombardi - Università Cattolica Del Sacro Cuore, Italy
 #30
  ROLE OF ANALITICAL TREATMENT INTERRUPTION ON HIV PERIPHERAL RESERVOIR DIVERSIFICATION
Claudia Alteri, PhD - University Of Milan, Italy
 #31
  Similar levels of HIV-DNA and residual viremia are found in virologically suppressed individuals who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-OnE Study
Maria Mercedes Santoro - University of Rome "Tor Vergata", Italy
 #32
    
 18:00 CET Poster viewing session 2  
    
 Satellite: Management of the COVID 19 Pandemic in Europe 
Moderator: Roger Paredes 
 
  20:00 CET Opening
  20:05 CET

Ravindra Gupta, MD, PhD

Diagnostics
Ravindra Gupta, MD, PhD
University of Cambridge, UK

  20:20 CET

Amanda Mocroft, PhD

Physiopathology and treatment
Xavier Lescure, MD, PhD
APHP, Paris, France

  20:35 CET

Carlo Federico Perno, MD, PhD

Clinical relevance of diagnostic testing
Carlo-Federico Perno, MD, PhD
Pediatric Hospital Bambino Gesù, Rome, Italy 

  20:50 CET

Abstract-drive presentation:

Comprehensive assessment of SARS-CoV-2 key genetic elements single or in clusters underlying geographically-dependent genetic evolutionary adaptation and their impact on drugs binding affinity and immune escape 
MOHAMMAD ALKHATIB, MD - Universta Di Roma Tor Vergata, Italy

 #33
  21:00 CET Faculty discussion 
  21:15 CET End of program 
 

Day 3 - Friday, 30 October 

 
 Session 4: Management of Viral Hepatitis
Chair: Rolf Kaiser
 
 14:00 CET

Treatment of Hepatitis B for HIV Clinicians
Anna Maria Geretti, MD, PhD - University of Liverpool, UK

 
 14:15 CETHepatitis C Resistance: Pro-Con Debate 
  

JM Pawlotsky, MD, PhD - University of Paris-Est, France

 
  

Francesca Ceccherini - Silberstein, PhDUniversity of Rome “Tor Vergata”, Italy

 
  14:45 CET

Anita Howe, PhD

HCV Nextstrain - a phylogenetic tool to  monitor HCV drug resistance and transmission
Anita Howe, PhD, British Columbia Centre For Diseases Control, Canada

 
  15:00 CETMolecular analysis of HCV subtype 3a dispersal patterns among inmates in Greece: HCV transmissions are not related to incarceration
Evangelia-Georgia Kostaki, PhD - Medical School, National and Kapodistrian University of Athens, Greece
 #10
  15:10 CETCharacterization and Resistance Profile of “Unusual” Hepatitis C Virus (HCV) Subtypes in Italy
Velia Chiara Di Maio, MD - University Of Rome Tor Vergata, Italy
 #11
  15:20 CETHighly sensitive digital droplet PCR assay allows to reveal cryptic HBV replication in anti-HBc positive/HBsAg negative patients with HIV infection.
Lorenzo Piermatteo, MD - "Tor Vergata" University Of Rome, Italy
 #12
 15:30 CET

Live Discussion

 
 15:50 CET

Break & Meet the Expert Session

 
     
 Session 5: What's in the Pipeline? Presentations from Scientists in the Industry
Chair: Jonathan Schapiro
 
 16:05 CETPhiladelphia Literacy
Kathleen Squires, MD
 
Global Director Scientific Affairs - ID/HIV, MSD, USA
 
 16:15 CETHanneke Schuitemaker,2019 120x160Hanneke Schuitemaker, PhD
Janssen, The Netherlands
 
 16:25 CET


Kirsten White, PhD

Senior Director, Clinical Virology, Gilead Sciences, USA

 
 16:35 CET


Michael Aboud, MBChB

Global Franchise Medical Head, ViiV Healthcare, UK

 
    
 16:45 CETLive Discussion 
 17:05 CETBreak 
    
 Session 6: PrEP and Resistance
Chair: Stephan Dressler
 
 17:15 CET

Gender neutral avatar 120x160
Overview of the current situation regarding PrEP and resistance
Speaker to be confirmed

 
 17:30 CET Round Table Discussion: Challenges to Widespread PrEP in Europe 
  

Clinical Aspects
Milosz Parczewski, MD, PhD - Pomeranian Medical University, Poland

 
  

  Meulbroek, Michael 2019
Social Aspects
Michael Meulbroek - BCN Checkpoint, Spain

 
  

Financial Consequence
Speaker to be confirmed

 
    
 18:00 CETClosure of the Workshop and Ricardo Camacho Awards